ANDRAŠINA, Tomáš, Josef JAROŠ, Tomáš JŮZA, Tomáš ROHAN, Dalibor ČERVINKA, Michal CRHA, Vlastimil VÁLEK and Nahum S. GOLDBERG. The Accumulation and Effects of Liposomal Doxorubicin in Tissues Treated by Radiofrequency Ablation and Irreversible Electroporation in Liver: In Vivo Experimental Study on Porcine Models. Cardiovascular and Interventional Radiology. NEW YORK: SPRINGER, 2019, vol. 42, No 5, p. 751-762. ISSN 0174-1551. Available from: https://dx.doi.org/10.1007/s00270-019-02175-z.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Accumulation and Effects of Liposomal Doxorubicin in Tissues Treated by Radiofrequency Ablation and Irreversible Electroporation in Liver: In Vivo Experimental Study on Porcine Models
Authors ANDRAŠINA, Tomáš (703 Slovakia, belonging to the institution), Josef JAROŠ (203 Czech Republic, belonging to the institution), Tomáš JŮZA (203 Czech Republic, guarantor, belonging to the institution), Tomáš ROHAN (203 Czech Republic, belonging to the institution), Dalibor ČERVINKA (203 Czech Republic), Michal CRHA (203 Czech Republic), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution) and Nahum S. GOLDBERG (376 Israel).
Edition Cardiovascular and Interventional Radiology, NEW YORK, SPRINGER, 2019, 0174-1551.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30224 Radiology, nuclear medicine and medical imaging
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.034
RIV identification code RIV/00216224:14110/19:00108469
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s00270-019-02175-z
UT WoS 000462586800014
Keywords in English Liposomal doxorubicin; Radiofrequency ablation; Irreversible electroporation
Tags 14110216, 14110517, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2020 16:22.
Abstract
PurposeTo compare the accumulation and effect of liposomal doxorubicin in liver tissue treated by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in in vivo porcine models.Materials and MethodsSixteen RFA and 16 IRE procedures were performed in healthy liver of two groups of three pigs. Multi-tined RFA parameters included: 100W, target temperature 105 degrees C for 7min. 100 IRE pulses were delivered using two monopolar electrodes at 2250V, 1Hz, for 100 mu sec. For each group, two pigs received 50mg liposomal doxorubicin (0.5mg/kg) as a drip infusion during ablation procedure, with one pig serving as control. Samples were harvested from the central and peripheral zones of the ablation at 24 and 72h. Immunohistochemical analysis to evaluate the degree of cellular stress, DNA damage, and degree of apoptosis was performed. These and the ablation sizes were compared. Doxorubicin concentrations were also analyzed using fluorescence photometry of homogenized tissue.ResultsRFA treatment zones created with concomitant administration of doxorubicin at 24h were significantly larger than controls (2.50.3cm vs. 2.2 +/- 0.2cm; p=0.04). By contrast, IRE treatment zones were negatively influenced by chemotherapy (2.2 +/- 0.4cm vs. 2.6 +/- 0.4cm; p=0.05). At 24h, doxorubicin concentrations in peripheral and central zones of RFA were significantly increased in comparison with untreated parenchyma (0.431 +/- 0.078 mu g/g and 0.314 +/- 0.055 mu g/g vs. 0.18 +/- 0.012 mu g/g; p<0.05). Doxorubicin concentrations in IRE zones were not significantly different from untreated liver (0.191 +/- 0.049 mu g/g and 0.210 +/- 0.049 mu g/g vs. 0.18 +/- 0.012 mu g/g).Conclusionsp id=Par4Whereas there is an increased accumulation of periprocedural doxorubicin and an associated increase in ablation zone following RFA, a contrary effect is noted with IRE. These discrepant findings suggest that different mechanisms and synergies will need to be considered in order to select optimal adjuvants for different classes of ablation devices.
Links
MUNI/A/1565/2018, interní kód MUName: Zdroje pro tkáňové inženýrství 9 (Acronym: TissueEng 9)
Investor: Masaryk University, Category A
NV15-32484A, research and development projectName: Využití nových biotechnologií v prevenci a léčbě stenóz žlučových cest
ROZV/24/LF/2018, interní kód MUName: LF - Příspěvek na IP 2108
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects
PrintDisplayed: 23/7/2024 17:41